Vinaykumar Tallavajhala
Neurology · Aurora, CONPI 1093343352
Payments from drug & device makers
What this record shows
This record is dominated by grants: $15,000 of the $24,726 with a category attached, or 60.7%. 27 manufacturers reported payments, led by Medtronic at 34.4% of the total. Reporting peaked in 2024 at $20,251 and has fallen 88.1% since, to $2,404 in 2025.
Across 106 payments — averaging $233.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Boston Scientific$8K
- Abbott$6K
- AstraZeneca$375
- Eisai Inc.$295
- SK Life Science, Inc.$147
- plus $1K from 21 others
What the payments were for
- Consulting fees$5,00020%
- Speaking & faculty fees$700%
- Grants$15,00061%
- Travel & lodging$2,2629%
- Food & beverage$2,39310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $8,511 |
| Boston Scientific | 4 | $7,742 |
| Abbott | 10 | $6,359 |
| AstraZeneca(2 entities) | 18 | $375 |
| Eisai Inc. | 14 | $295 |
| SK Life Science, Inc. | 5 | $147 |
| Jazz Pharmaceuticals Inc. | 6 | $135 |
| Biogen | 8 | $133 |
| Teva Pharmaceuticals USA, Inc. | 1 | $129 |
| Lilly USA, LLC | 2 | $129 |
| Amneal Pharmaceuticals LLC | 1 | $120 |
| Tanabe Pharma America, Inc. | 7 | $106 |
| AbbVie | 4 | $95 |
| Argenx US, Inc. | 1 | $93 |
| Acorda Therapeutics, Inc | 5 | $86 |
| Amgen | 3 | $51 |
| Neurocrine Biosciences, Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Neurelis, Inc. | 1 | $22 |
| Novartis | 1 | $22 |
| UCB, Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Pfizer | 1 | $15 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,726 in reported general payments places this provider in the 80th percentile of 334 neurology providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 34 | $1,482 |
| Baclofen | 13 | $446 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 11 | $407 |
| Gabapentin | 18 | $381 |
| Levetiracetam | 12 | $313 |
| Doxepin Hcl | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Other neurology in Aurora
- Jeffrey BennettAurora$605K
- Enrique AlvarezAurora$407K
- Anna ShahAurora$157K
- Timothy VollmerAurora$136K
- Simon OhAurora$112K
- Amanda PiquetAurora$106K
- Brent MorelAurora$79K
- Drew KernAurora$68K
- Ondrea TimmermannAurora$33K
- Thomas RagoleAurora$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.